Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Envelope glycoprotein gp41 is a transmembrane protein that forms part of the envelope glycoprotein complex (Env) of human immunodeficiency virus type 1 (HIV-1). It is non-covalently associated with the surface subunit gp120. While gp120 mediates viral attachment to host cell receptors, gp41 is responsible for catalyzing the fusion between viral and cellular membranes, a critical step in HIV entry into target cells. The core structure of activated/fusion-active gp41 is a six-helical bundle: three HR1 helices form an interior coiled-coil trimer, while three HR2 helices pack antiparallel into hydrophobic grooves on this trimer. This conformation brings viral and cellular membranes close together to facilitate fusion. Mutations within conserved residues such as Q563 in HR1 can significantly affect fusogenic activity and infectivity.
Inhibition of gp41-mediated membrane fusion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envelope glycoprotein gp41 (None).